CASI Pharmaceuticals Valuation
| CASI Stock | USD 0.24 0.03 14.29% |
CASI Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of CASI Pharmaceuticals from examining the entity fundamentals such as Profit Margin of (1.84) %, return on asset of -0.62, and Shares Outstanding of 15.49 M as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting CASI Pharmaceuticals' valuation include:
Price Book 11.2089 | Enterprise Value | Enterprise Value Ebitda 0.0687 | Price Sales 0.1197 | Enterprise Value Revenue 0.7137 |
Undervalued
Today
Please note that CASI Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of CASI Pharmaceuticals is based on 3 months time horizon. Increasing CASI Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CASI Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CASI Stock. However, CASI Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.24 | Real 1.18 | Target 4.0 | Hype 0.23 | Naive 0.19 |
The intrinsic value of CASI Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence CASI Pharmaceuticals' stock price.
Estimating the potential upside or downside of CASI Pharmaceuticals helps investors to forecast how CASI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CASI Pharmaceuticals more accurately as focusing exclusively on CASI Pharmaceuticals' fundamentals will not take into account other important factors: When choosing an evaluation method for CASI Pharmaceuticals, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
CASI Pharmaceuticals Cash |
|
CASI Pharmaceuticals Total Value Analysis
CASI Pharmaceuticals is currently projected to have valuation of 19.16 M with market capitalization of 3.21 M, debt of 22.14 M, and cash on hands of 24.57 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the CASI Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
19.16 M | 3.21 M | 22.14 M | 24.57 M |
CASI Pharmaceuticals Investor Information
About 87.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.02. CASI Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 2nd of June 2022. Based on the key indicators related to CASI Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, CASI Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.CASI Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CASI Pharmaceuticals has an asset utilization ratio of 53.17 percent. This signifies that the Company is making $0.53 for each dollar of assets. An increasing asset utilization means that CASI Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.CASI Pharmaceuticals Profitability Analysis
Based on CASI Pharmaceuticals' profitability indicators, CASI Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in April. Profitability indicators assess CASI Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 1995-03-31 | Previous Quarter -13.4 M | Current Value -10.9 M | Quarterly Volatility 5.7 M |
For CASI Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CASI Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CASI Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CASI Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CASI Pharmaceuticals over time as well as its relative position and ranking within its peers.
CASI Pharmaceuticals Earnings per Share Projection vs Actual
By analyzing CASI Pharmaceuticals' earnings estimates, investors can diagnose different trends across CASI Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for CASI Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.CASI Pharmaceuticals Ownership Allocation
CASI Pharmaceuticals holds a total of 15.49 Million outstanding shares. CASI Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 87.26 percent of CASI Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Also note that nearly three million seventy-five thousand three hundred seventeen invesors are currently shorting CASI Pharmaceuticals expressing very little confidence in its future performance.CASI Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 28.54 M. Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 9.61 M.About CASI Pharmaceuticals Valuation
An absolute valuation paradigm, as applied to CASI Stock, attempts to find the value of CASI Pharmaceuticals based on its fundamental and basic technical indicators. By analyzing CASI Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of CASI Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of CASI Pharmaceuticals. We calculate exposure to CASI Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CASI Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 12.8 M | 13.5 M | |
| Pretax Profit Margin | (1.53) | (1.61) | |
| Operating Profit Margin | (1.25) | (1.19) | |
| Net Loss | (1.58) | (1.66) | |
| Gross Profit Margin | 0.45 | 0.69 |
CASI Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of CASI Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CASI we look at many different elements of the entity such as CASI's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as CASI Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use CASI Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes CASI Pharmaceuticals' worth.Complementary Tools for CASI Stock analysis
When running CASI Pharmaceuticals' price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |